

29 November 2013 ASX Release

Actinogen Limited (ASX Code: ACW) Results of Annual General Meeting

The Annual General Meeting of Actinogen Limited was held today at 10.00 am Perth time at 108 Outram Street, West Perth, Western Australia.

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporation Act, details of the resolutions and the proxies received in respect of each resolution are set out in the summary below:

1. Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
12,434,748	91.63%	710,000	5.23%	4,000	0.03%	422,666	3.11%

The motion was carried on a show of hands as a non-binding resolution.

2. Consolidation of Capital

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,139,912	96.66%	719,000	1.14%	15,000	0.02%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

3. Approval to Issue Shares Under the Share Placement

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
57,306,912	98.98%	150,000	0.26%	17,000	0.03%	422,666	0.73%

The motion was carried on a show of hands as an ordinary resolution.

4. Approval to Issue New Options Under Option Placement

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
56,365,912	95.78%	1,103,000	1.87%	5,000	0.01%	1,378,772	2.34%

The motion was carried on a show of hands an ordinary resolution.

5. Approval to Participate in the Share Placement – Mr Daniel Parasiliti

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,129,912	96.64%	740,000	1.17%	4,000	0.01%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

6. Approval to Participate in the Share Placement - Dr Brendan de Kauwe

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,129,912	98.13%	736,000	1.18%	4,000	0.01%	422,666	0.68%

The motion was carried on a show of hands as an ordinary resolution.

7. Approval to Issue Shares in Satisfaction of Debt

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
54,793,912	96.55%	564,000	0.99%	16,000	0.03%	1,378,772	2.43%

The motion was carried on a show of hands as an ordinary resolution.

8. Ratification of Prior Issue - Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
50,377,912	96.23%	575,000	1.10%	21,000	0.04%	1,378,772	2.63%

The motion was carried on a show of hands as an ordinary resolution.

9. Approval of 10% Placement Capacity

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,270,912	96.87%	583,000	0.92%	20,000	0.03%	1,378,772	2.18%

The motion was carried on a show of hands as a special resolution.

10. Re-Election of Director - Mr Daniel Parasiliti

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,287,912	96.90%	110,000	0.17%	476,000	0.75%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

11. Re-Election of Director - Dr Brendan de Kauwe

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,287,912	96.90%	110,000	0.17%	476,000	0.75%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

12. Re-Election of Director – Mr David Zohar

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
60,665,212	95.91%	236,700	0.37%	972,000	1.54%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

13. Adoption of New Constitution

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,316,912	96.94%	70,000	0.11%	472,000	0.75%	1.393,772	2.20%

The motion was carried on a show of hands as a special resolution.

14. Re-Appointment of Auditor

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For		Against		Abstention		Proxy's Discretion	
61,861,912	97.80%	-	-	12,000	0.02%	1,378,772	2.18%

The motion was carried on a show of hands as an ordinary resolution.

For further information, contact:

Peter Webse

Company Secretary Tel: +61 8 9481 3860

About Actinogen Limited

Actinogen Limited (ASX: ACW)

Actinogen is dedicated to the discovery and isolation of a group of environmental bacteria known as the Actinomycetes. Actinomycetes have been shown to be able to use a wide range of unusual nutritional resources and often produce bioactive molecules as a by-product that have been proven to be useful to man; including well known commercial examples such as bacterial antibiotics, anti fungal agents, anticancer agents and a variety of other chemicals that are used in the control of physiological and physical processes.

In addition, there are examples of Actinomycetes that can degrade industrial wastes such as oils, tar, domestic and industrial waste, and the rehabilitation of oil spills. Actinogen has proven high-level expertise in the discovery and isolation of Actinomycetes from WA soils and in the detection of bioactive molecules they produce. During 2011, Actinogen began a bio-ethanol research program, which has had very encouraging results and to date is a focal project for the company. The Company's strategy is to collaborate with groups nationally and internationally who are active in the development of technology that is synergistic with or that could utilise the Company's current Actinomycetes research projects and exclusive intellectual property.